Home›Clinical trials›Maryland

GLP-1 clinical trials in Maryland: 22 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

22 GLP-1 clinical trials are recruiting at 27 sites in 9 cities across Maryland. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Maryland

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    3 sites in Maryland

    • Johns Hopkins School of Medicine, Baltimore. 443-927-8723
    • MedStar Health Research Institute - Good Samaritan Hospital, Baltimore. 443-444-2263
    • MedStar Union Memorial Hospital, Baltimore. 410-554-4451

    NCT05390892 on ClinicalTrials.gov. See whether you qualify.

  2. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    2 sites in Maryland

    NCT06864026 on ClinicalTrials.gov. See whether you qualify.

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Eli Lilly and Company plans to enroll 200 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Maryland

    • Dermatology and Skin Cancer Specialists, LLC, Rockville

    NCT06857942 on ClinicalTrials.gov. See whether you qualify.

  1. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    2 sites in Maryland

    • Mercy Medical Center - Baltimore, Baltimore. 410-332-9356
    • Capital Digestive Care - Chevy Chase, Chevy Chase. 301-841-6869

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  2. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    2 sites in Maryland

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    1 site in Maryland

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  4. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Maryland

    • Johns Hopkins Children's Center, Baltimore

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  5. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Eli Lilly and Company plans to enroll 350 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Maryland

    • Capital Digestive Care - Chevy Chase, Chevy Chase

    NCT06937086 on ClinicalTrials.gov. See whether you qualify.

  6. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Eli Lilly and Company plans to enroll 290 participants.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Maryland

    • Capital Digestive Care - Chevy Chase, Chevy Chase

    NCT06937099 on ClinicalTrials.gov. See whether you qualify.

  7. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Maryland

    • Barry J. Reiner, MD LLC, Baltimore

    NCT07253285 on ClinicalTrials.gov. See whether you qualify.

The other 12 studies recruiting in Maryland

  1. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Maryland

    • Endo and Metabolic Consultants, Rockville

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

  2. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Maryland

    • Research Site, Rockville

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  3. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Boehringer Ingelheim plans to enroll 600 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Maryland

    • Endocrine and Metabolic Consultants, Rockville. 833-602-2368

    NCT07754461 on ClinicalTrials.gov. See whether you qualify.

  4. Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Phase 2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) plans to enroll 104 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in Maryland

    • National Institutes of Health Clinical Center, Bethesda. 800-411-1222

    NCT03884075 on ClinicalTrials.gov. See whether you qualify.

  5. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Milton S. Hershey Medical Center plans to enroll 200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in Maryland

    • University of Maryland Baltimore, Baltimore

    NCT06548490 on ClinicalTrials.gov. See whether you qualify.

  6. Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

    Phase 2. University of Maryland, Baltimore plans to enroll 40 participants.

    A study of a GLP-1 medicine, semaglutide, in people with cocaine use disorder.

    Who can join. Adults 18 to 65, have cocaine use disorder, BMI 20+.

    1 site in Maryland

    • Institute of Human Virology at the University of Maryland School of Medicine, Baltimore. 443-635-4943

    NCT06691243 on ClinicalTrials.gov. See whether you qualify.

  7. Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

    Phase 2. Johns Hopkins University plans to enroll 105 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with binge eating disorder lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    1 site in Maryland

    NCT06847399 on ClinicalTrials.gov. See whether you qualify.

  8. Tirzepatide in MetALD

    Phase 2. National Institute on Alcohol Abuse and Alcoholism (NIAAA) plans to enroll 120 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 21+, have metabolic alcohol-associated liver disease, BMI 25+.

    1 site in Maryland

    • National Institutes of Health Clinical Center, Bethesda. 800-411-1222

    NCT07046819 on ClinicalTrials.gov. See whether you qualify.

  9. Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Phase 2. Johns Hopkins University plans to enroll 120 participants.

    A study of an investigational medicine, NLY01, in people with multiple sclerosis.

    Who can join. Adults 18 to 60, have multiple sclerosis, BMI 27+.

    1 site in Maryland

    NCT07497399 on ClinicalTrials.gov. See whether you qualify.

  10. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Novo Nordisk A/S plans to enroll 230 participants.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Maryland

    • Endo And Metab Cons, Rockville

    NCT07639021 on ClinicalTrials.gov. See whether you qualify.

  11. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Novo Nordisk A/S plans to enroll 300 participants.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Maryland

    • MD Medical Research, Oxon Hill

    NCT07668388 on ClinicalTrials.gov. See whether you qualify.

  12. Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

    Phase 1. National Institute on Alcohol Abuse and Alcoholism (NIAAA) plans to enroll 176 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with alcohol use disorder drink less.

    Who can join. Adults 21 to 65, have alcohol use disorder, BMI 23+.

    1 site in Maryland

    • National Institutes of Health Clinical Center, Bethesda. 800-411-1222

    NCT07559500 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.